Galectin-3 in Patients With Paroxysmal and Persistent Atrial Fibrillation and Metabolic Syndrome

• Published in: Kardiologiia Vol. 56; no. 6; p. 41
• Main Authors: A, V A, Zaslavskaya, E L, Soboleva, A V, Baranova, E I, Listopad, O V, Nifontov, S E, Nrady, A O, Shlyakhto, E V
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 01-06-2016
• Subjects: Adult; Aged; Anti-Arrhythmia Agents - therapeutic use; Atrial Fibrillation - blood; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Biomarkers; Female; Galectin 3 - blood; Humans; Male; Metabolic Syndrome - blood; Metabolic Syndrome - complications; Middle Aged; metabolic syndrome; atrial fibrillation; marker of fibrosis; galectin 3
• ISSN: 0022-9040
• DOI: 10.18565/cardio.2016.6.17-22

To evaluate serum galectin 3 and to determine the potential clinical value of this parameter in patients with atrial fibrillation - AF (paroxysmal and persistent) and metabolic syndrome (MS).
We examined 100 patients with MS (50 with paroxysmal or persistent AF and 50 without arrhythmia) and 50 healthy persons. Serum galectin 3 measured by ELISA method, ECHO cardiography was performed to all examined persons.
Galectin 3 in patients with MS and AF was higher, than in patients with MS without arrhythmia and much more higher than galectin 3 in healthy persons 0,72 (0,44;1,36), 0,44 (0,42;1,22) and 0,32 (0,28;0,42) ng/ml (<0,01). In patients with persistent AF levels of galectin 3 is higher than in patients with paroxysmal AF. Positive correlation between the levels of galectin 3 and duration arrhythmia was revealed (r=0,301; p<0,01). Higher level of galectin 3 was revealed in patients with frequent paroxysms of AF and ineffective antiarrhythmic therapy.
Marker of myocardial fibrosis serum galectin 3 in patients with atrial fibrillation and metabolic syndrome is higher than in patients with the metabolic syndrome, without this arrhythmia and higher than in healthy controls. In patients with persistent AF level of galectin 3 was higher than in patients with paroxysmal AF.